EGFR and hepatocellular carcinoma: Investigators have used several different methods to block the expression of EGFR, the kinase activity of EGFR, or its autocrine activation, thereby increasing the sensitivity of EGFR-positive resistant cells to sorafenib, further demonstrating that EGFR is a potential determinant of sorafenib resistance in HCC cells.